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Efficacy of imidacloprid 10%/moxidectin 
1% spot-on formulation (Advocate®) 
in the prevention and treatment of feline 
aelurostrongylosis
Lea Heuer1, Gabriele Petry1, Matthias Pollmeier1, Roland Schaper1, Katrin Deuster1, Holger Schmidt2, 
Katrin Blazejak3, Christina Strube3, Angela Di Cesare4, Donato Traversa4, Manuela Schnyder5, 
Janina McKay‑Demeler6,7, Georg von Samson‑Himmelstjerna6, Sandra Mangold‑Gehring1* and Claudia Böhm1
Abstract 
Background: In three randomized, controlled laboratory efficacy studies, the efficacy in the prevention of patent 
infections of a topical combination of imidacloprid 10%/moxidectin 1% (Advocate® spot‑on formulation for cats, 
Bayer Animal Health GmbH) against larval stages and immature adults of Aelurostrongylus abstrusus, as well as the 
treatment efficacy of a single or three monthly treatments against adult A. abstrusus, were evaluated.
Methods: Cats were experimentally inoculated with 300–800 third‑stage larvae (L3). Each group comprised 8 
animals and the treatment dose was 10 mg/kg bodyweight (bw) imidacloprid and 1 mg/kg bw moxidectin in each 
study. Prevention of the establishment of patent infections was evaluated by two treatments at a monthly interval at 
three different time points before and after challenge infection. Curative efficacy was tested by one or three treat‑
ments after the onset of patency. Worm counts at necropsy were used for efficacy calculations.
Results: In Study 1, the control group had a geometric mean (GM) of 28.8 adult nematodes and the single treatment 
group had a GM of 3.4 (efficacy 88.3%). In Study 2, the control group had a GM of 14.3, the prevention group had a 
GM of 0 (efficacy 100%), while the treatment group had a GM of 0.1 (efficacy 99.4%). In Study 3, the GM worm burden 
in the control group was 32.6 compared to 0 in all three prevention groups (efficacy 100% for all of those groups).
Conclusions: The monthly administration of Advocate® reliably eliminated early larval stages and thereby prevented 
lung damage from and patent infections with A. abstrusus in cats. Regarding treatment, a single application of Advo‑
cate® reduced the worm burden, but it did not sufficiently clear the infection. In contrast, three monthly treatments 
were safe and highly efficacious against A. abstrusus.
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Background
Parasitic respiratory diseases are of increasing impor-
tance in feline clinical practice [1]. Over recent years, 
the number of reports of feline lungworm infections has 
risen worldwide, particularly across mainland Europe. 
Concerning parasitic helminths of the feline respira-
tory tract, such as Oslerus rostratus, Troglostrongylus 
spp. or Capillaria aerophila, Aelurostrongylus abstrusus 
remains the most important of the feline lungworms in 
both clinical and epidemiological terms [1, 2]. This nema-
tode is distributed worldwide with varying prevalence 
rates in cats, e.g. 1.7% in the UK [3], 5.1% in the USA 
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[4], approximately 8% in Denmark [5] or Greece [6], and 
between 10 and 38.3% in Italy [7]. The parasite may infect 
domestic cats and occasionally wild felids, e.g. European 
wildcats or lions [2, 8, 9].
Generally, the risk of infection is higher for stray or 
free-roaming cats in endemic areas [10–12]. Infections 
may be acquired by ingestion of either the intermedi-
ate hosts (mollusks) or paratenic hosts, such as birds, 
rodents, amphibians or reptiles [13–16]. Besides the 
adult nematodes, which reside mainly in the bronchi-
oles, alveolar ducts and lung parenchyma, egg production 
and migrating larvae can also cause inflammatory lung 
lesions, depending on the infective dosage [17]. Infec-
tions can range from subclinical or severe to fatal. Clini-
cal manifestations include non-specific signs compatible 
with a systemic disease, such as apathy, depression and 
weight loss, as well as respiratory alterations, e.g. dysp-
nea, panting, coughing, sneezing and nasal discharge [15, 
18, 19]. Concerning bronchoscopy findings, bronchiecta-
sis and mucus accumulation were found in cats infected 
with A. abstrusus [20]. Cardiac presentations, such as 
right-sided cardiomegaly, heart murmurs and pulmonary 
hypertension, have also been described in kittens [21]. 
Furthermore, spontaneous death during anesthesia has 
also been associated with lungworm disease in cats [22]. 
Severe cardiopulmonary disease or fatalities can be the 
result of a late diagnosis and treatment of aelurostrongy-
losis [1].
Ideally, infections should be prevented or treated at an 
early stage with adequate actives. Routine deworming is 
therefore advisable, especially in free-roaming cats with 
respiratory signs. Data on the efficacy of treatments are 
available from clinical studies and case reports, but infor-
mation on preventive properties of the licensed prod-
ucts is limited. Use of an oral formulation of milbemycin 
oxime and praziquantel (Milbemax®, Elanco Europe, 
Bad Homburg, Germany) stopped larval shedding and 
resolved clinical signs in a single case after two applica-
tions two weeks apart [21]. Selamectin 45  mg spot-on 
formulation (Stronghold®, Zoetis, Berlin, Germany; dose 
range 2.6–7.5 kg body weight, bw) was used twice 23 days 
apart in naturally infected cats and stopped larval shed-
ding in 9 out of 10 cats [23]. Of the benzimidazoles, an 
oral paste with 18.75% fenbendazole (Panacur®; MSD 
Animal Health, Unterschleißheim, Germany) is licensed 
in the UK, among other countries, for the treatment of 
feline aelurostrongylosis. In two field studies [24, 25], an 
efficacy of 99.3% has been reported with the oral treat-
ment of 50  mg/kg bw daily for 3 consecutive days. In 
these field studies, a single application of an emodepside/
praziquantel (Profender®, Bayer Animal Health GmbH, 
Leverkusen, Germany) spot-on formulation at a dosage of 
3 mg/kg emodepside and 12 mg/kg praziquantel showed 
a comparable efficacy, i.e. 99.4%, to the oral fenbendazole 
treatment in terms of larval shedding [25]. The emodep-
side formulation has been evaluated further in two ran-
domized, placebo-controlled experimental studies. Two 
spot-on administrations at a two-week interval showed a 
99.2% reduction of worm counts in the lung tissue [26]. 
Profender® is therefore licensed for the treatment of 
adult stages of A. abstrusus in cats with this treatment 
regimen [27]. Another product licensed for the treatment 
of A. abstrusus (L3, L4 and adults) is a topical formula-
tion containing fipronil 8.3% w/v, (S)-methoprene 10% 
w/v, eprinomectin 0.4% w/v and praziquantel 8.3% w/v 
(Broadline®, Merial, Hallbergmoos, Germany), which 
had an efficacy of 99.6% against adult A. abstrusus [28, 
29]. Knaus et al. [28] also demonstrated an efficacy with 
this formulation of 98.9%, 99.3% and 91.6% against L3, L4 
and immature adults of A. abstrusus, respectively, show-
ing the preventive potential against patent A. abstrusus 
infections.
Because of its longer half-life and its good safety 
profile, moxidectin has been suggested as another 
potential option for the chemoprevention of aeluro-
strongylosis. This drug remains detectable in plasma 
samples for weeks and consistent monthly administra-
tions of topical moxidectin can induce elevated and sus-
tained steady-state plasma concentrations in dogs and 
cats [30–32]. Furthermore, moxidectin has proven to be 
highly effective against patent A. abstrusus infections: in 
a field study, a spot-on formulation containing 10% imi-
dacloprid and 1% moxidectin (Advocate®; Bayer Animal 
Health GmbH) showed 100% efficacy in reducing larval 
shedding and resolving clinical signs after a single treat-
ment [24]. This formulation (Advocate®, Bayer Animal 
Health GmbH) is licensed in some markets (e.g. New 
Zealand, Australia) for the treatment and control of A. 
abstrusus in cats [33, 34].
The controlled laboratory studies reported here were 
conducted to investigate the efficacy of this formulation 
in the treatment and prevention of patency in cats exper-
imentally infected with A. abstrusus.
Methods
Study design
To evaluate imidacloprid 10%/moxidectin 1% spot-on 
formulation for the prevention (against L3 and L4 larvae) 
and treatment (adults) of patent experimental A. abstru-
sus infections in cats, three studies were conducted. An 
overview is given in Fig. 1 and Table 1.
Studies were conducted in accordance with VICH 
Guideline 9, “Good Clinical Practice” (July 2001) [35], 
VICH Guideline 7, “Efficacy of anthelmintics: general 
requirements” [36] and VICH Guideline 20, “Efficacy of 
anthelmintics: specific recommendations for felines” [37]. 
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The study procedures adhered to the WAAVP guidelines 
for evaluating the efficacy of anthelmintics in dogs and 
cats [38]. The study design was based on the scientific 
knowledge and experience gained in a similar study [26], 
because the guidelines do not include specific informa-
tion on A. abstrusus.
Study 1
Study 1 evaluated the efficacy of a single treatment 
against A. abstrusus infections in cats after the onset 
of patency. The study was performed as a placebo-con-
trolled, randomized and blinded laboratory study.
Study 2
In Study 2, the treatment and the prevention effect of 
imidacloprid 10%/moxidectin 1% spot-on formulation 
were examined. In the prevention group, the cats were 
treated before and after inoculation. In the second group, 
the treatment efficacy was examined by applying the 
spot-on formulation after the onset of patency and twice 
thereafter at monthly intervals. The control group was 
not treated and blinding was only applied to necropsy 
procedures
Study 3
Study 3 evaluated the ability of imidacloprid 10%/mox-
idectin 1% spot-on formulation to prevent the patent 
infection when administered monthly for two consecu-
tive months, starting before the cats were experimentally 
infected with A. abstrusus L3. The study was performed 
as a placebo-controlled, randomized and blinded labora-
tory study.
Study Day (SD) 
Event
Study No. 1*
Study No. 2*
Study No. 3*
-43                 -36   -20                 -10        -4       0             7            14     18  21  24     28           32       34    36             48       53          81          109          136   
// // // // // ////
800
300
300
300
300
300
= Lung dissection= Patent infection= Treatment= Inoculation
(no of L3)
*All studies had an additional control group not shown here
between SDs 34 and 50 
between SDs 34 and 50 
between SDs 
40 and 50 
between SDs 
136 and 140 
between SDs 
62 and 66 
between SDs 34 and 50 
Fig. 1 Overview of the study designs of the three experimental laboratory studies
Table 1 Overview on study designs of the three laboratory studies
Study Inoculation dose 
(L3)
Inoculation (study 
day)
Study group Treatment Study day Necropsy (study day)
1 800 0 1.1 Placebo 36 62–66
1.2 Advocate® 36
2 300 0 2.1 Untreated control 136–140
2.2 Advocate® − 10; 18
2.3 Advocate® 53; 81; 109
3 300 0 3.1 Placebo − 4; 24 48–50 (20 cats)
3.2 Advocate® − 4; 24 34–35 (12 cats)
3.3 Advocate® − 10; 18 48–50
3.4 Advocate® − 20; 8 48–50
Page 4 of 10Heuer et al. Parasites Vectors           (2020) 13:65 
Study animals
The cats used in all three studies were purpose-bred and 
either owned by the study facility or purchased from 
commercial breeders. The sex of the included animals 
was distributed across the studies as follows: 8 females/8 
males in Study 1; 17 females/7 males in Study 2; 16 
females/16 males in Study 3.
All cats were acclimatized at least 7 days before study 
inclusion. On the day of infection, the animals were aged 
less than 10  months. They had been vaccinated against 
major feline infectious diseases and they were dewormed 
once with pyrantel embonate (Banminth®, Study 1) or 
with pyrantel embonate and praziquantel (Drontal®, 
Studies 2 and 3) before the start of the study. Fecal sam-
ples were examined during the acclimatization period to 
verify successful deworming. Cats included in the stud-
ies were not allowed to have been recently treated with 
drugs (e.g. macrocyclic lactones) which could interfere 
with the investigational product.
Animals were group-housed in their respective study 
groups, but were housed individually on the day of treat-
ment, for two consecutive days and for individual fecal 
sample collection. Pens were equipped with planks and 
boxes. Toys and scratching places were offered for envi-
ronmental enrichment. The animals received standard 
commercial wet and/or dry food and water was available 
ad libitum. Handling and housing were performed in 
accordance with national animal welfare regulations.
Allocation and treatment
All treatments in the three studies were administered 
with the minimum treatment dose of 10 mg/kg BW imi-
dacloprid and 1  mg/kg BW moxidectin, corresponding 
to 0.1 ml of the spot-on formulation of Advocate® per kg 
BW.
In Study 1, the cats were randomly allocated to one 
of two study groups, with each group containing eight 
animals. The cats were first separated by sex and then 
ranked in descending order based on their highest fecal 
L1 count on study day (SD) 2 and 4. After randomiza-
tion, each study group consisted of four male and four 
female cats. Treatment was administered once on SD 
0, 36 days post-infection (dpi), once all cats had shown 
a positive fecal larval count. The cats in the treatment 
group received one dose of the recommended minimum 
treatment doses, while cats in the control group received 
a placebo formulation at a dose of 0.1 ml/kg bw.
In Study 2, 24 cats were randomly allocated to one of 
three study groups of 8 animals each, based on sex and 
body weight. To evaluate the prevention efficacy, treat-
ment of the cats assigned to group 2 was administered 
twice on SD 10 (10 days prior to infection) and on SD 18 
(18 dpi) (see Table 1). To evaluate the treatment efficacy, 
the cats in group 3 were treated three times at monthly 
intervals on SD 53, SD 81 and on SD 109. The cats assigned 
to the control group (group 1) were left untreated.
In Study 3, 32 cats were randomly allocated to one of 
four study groups, based on their sex and ranking accord-
ing to body weight and animal ID. After randomization, 
each group consisted of 8 cats with equal sex distribu-
tion. The cats in the three treatment groups received a 
dose of the minimum treatment dose, whereas the cats 
in the control group were treated with a placebo formu-
lation. The preventive efficacy of the imidacloprid 10%/
moxidectin 1% spot-on formulation in the elimination 
of early larval stages (L3 and/or L4) of A. abstrusus was 
evaluated. Therefore, the cats assigned to group 1 (con-
trol) and group 2 were treated on SD 4 and on SD 24, 
group 3 was treated on SD 10 and SD 18 and group 4 on 
SD 20 and on SD 8.
Health observations
All cats were handled and observed by the animal care-
takers for their general health once daily from the begin-
ning of the respective study to the day of necropsy for 
each individual. The animals were physically examined at 
least once before infection, before treatment and before 
necropsy. Only healthy cats were included in the studies. 
On treatment days, the cats were clinically assessed for 
adverse events at least twice at the start of treatment and 
up to 5 h afterwards.
Experimental infections
The cats were experimentally inoculated before treat-
ment with 800 (group 1.1 and 1.2) or 300 (group 2.3), 
or after treatment with 300 (groups 2.2 and 3.2, 3.3, 
3.4) infective L3 of A. abstrusus (see Table  1). Due to 
animal welfare reasons, the number of larvae used for 
inoculation was reduced from 800 (Study 1) to 300 
(Studies 2 and 3). The L3 were obtained by diges-
tion of the experimentally infected snails. The snails 
had been experimentally infected with L1 which were 
obtained from naturally infected cats. The snails were 
cut into pieces and the snail tissue was minced and 
then digested for 20–30 min in HCl solution with pep-
sin at approximately 41 °C: 0.4–0.6 g pepsin was mixed 
in 100  ml Aqua Bidest and 0.7  ml of 37% HCl solu-
tion. The digested material was passed through a 180 
µm sieve and centrifuged at 500×g for 5 min before 
the supernatant was discarded. A number of subsam-
ples were counted under a stereo microscope. Indi-
vidual inoculation doses for the cats were prepared 
and applied intragastrically via a stomach tube. The 
cats were anesthetized before inoculation with a com-
bination of medetomidine (0.008 mg/kg bw) and keta-
mine (10  mg/kg bw) with or without premedication 
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with acepromazine (0.15  mg/kg bw). In order to pre-
vent vomiting or regurgitation, the cats received meto-
clopramide (0.3  mg/kg bw) intramuscularly. The cats 
were observed for vomiting or regurgitation for 60 min 
after inoculation. During these first 60 min, vomiting 
occurred in some cats (seven cats in Study 1, three cats 
in Study 3), but the amount of vomit was small (< 1 ml). 
In Study 3, two of the three cats were re-inoculated 
with 150 and 120 L3 based on the amount of vomit and 
larval counts in the vomit. In Study 1, the cats which 
had vomited were not re-inoculated, but as two cats 
showed spillage during inoculation, they were re-dosed 
with approximately 150 L3. In Study 2, none of the cats 
showed any vomiting within the first 60 min of inocula-
tion. Between 2 and 3 h after inoculation, the majority 
of cats vomited; no re-inoculation was performed.
Fecal examination
The feces of all cats had to be negative for nematode eggs 
and larvae before study inclusion and inoculation with 
A. abstrusus. To demonstrate the negative parasitologi-
cal status of the individual cat, at least one fecal sample 
was examined using a combined sedimentation/flotation 
method and the Baermann technique during the acclima-
tization period. In Study 1, L1 counts were determined by 
a slightly modified quantitative Baermann technique. An 
exact amount of 4–10 g was used, 14 ml of fluid was taken 
from the sediment of the funnel and was centrifuged at 
500×g for 2 min. The supernatant was discarded and, if 
the number of larvae was low, the whole sediment was 
screened, or if the number of larvae was high, an aliquot 
was screened for larvae and the total number calculated. 
The determined larval counts were additionally used for 
the randomization of cats.
Post-treatment fecal examinations were conducted as 
follows: in Study 1, starting at 30 dpi, pooled fecal sam-
ples per cage, i.e. two animals, were examined using the 
Baermann technique and once the fecal samples were 
positive for L1, individual fecal samples were collected 
and examined. In Study 2, individual fecal samples were 
collected and examined every other day between SD 
40 and 48 (study groups 2.1, 2.3) or rather SD 50 (study 
group 2.2) to detect the start of patency. In Study 3, post-
treatment fecal examinations were conducted on the day 
of necropsy.
Necropsy
In the three studies, necropsy was performed on several 
consecutive study days, depending on the days of treat-
ment (details in Table 1). The lungs and heart of each cat 
were completely removed. All lung lobes were cut into 
pieces of approximately 1  cm3 and pieces were divided 
into two approximately equal portions. Lung tissue was 
checked for lungworms under a stereomicroscope by 
dissecting each piece with scalpel and forceps. The two 
portions of each lung piece were analyzed by at least two 
different persons in order to randomize the potential dif-
ferences in the dissection technique. Lungworms were 
identified according to species, observed for viability 
and counted. If larval or pre-adult stages were present, 
this was also recorded and, if necessary, verified under 
an optical microscope. As worms can embed themselves 
very deeply into the lung parenchyma, it had to be con-
sidered that originally viable worms could have been 
destroyed and cut into pieces during isolation from lung 
tissue. Worms could have also died because of the long 
duration of the complicated worm counting procedure. 
To evaluate viability and the onset of death, each lung-
worm, or part of a worm, was carefully examined under 
a stereomicroscope. Viability/motility, general appear-
ance and structure of the integument were assessed. 
All viable worms and all recently-dead intact worms or 
worm pieces with intact integument were counted as 
viable worms. Specimens of A. abstrusus which were 
obviously dead before necropsy started (i.e. lytic worms 
with marked changes of the cuticle) were counted as dead 
worms. In the case of worm parts, these were differenti-
ated between nematode heads and/or tails. Each present 
head and/or tail was counted. If the number of heads was 
greater than the number of present tails, the heads were 
used to calculate the total number of worms. If the num-
ber of tails was greater, the tails were used for this cal-
culation. Total worm counts determined in necropsy are 
listed in Additional file 1.
Efficacy and statistical analysis
As per specification in VICH Guidelines 7 and 20 [33, 
34], the adequacy of infection was achieved when at 
least six cats in the control group were confirmed to be 
infected and when the lower 95% confidence intervals of 
the geometric means were greater than 10% of the geo-
metric means.
Percent efficacy was calculated according to the recom-
mendations for controlled tests described in the above-
mentioned guidelines:
where N1 is the geometric mean worm count for the 
treatment group and N2 is the geometric mean worm 
count for the control group.
The geometric mean could not be calculated if the 
worm count values equaled zero. Due to this fact, a 
translation of all values was performed by adding 1 to 
the number of worm counts prior to logarithmic trans-
formation and 1 was subtracted from the antilog value 
% Effectiveness (reduction) = (N2 − N1)/N2× 100
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to meaningfully represent the geometric mean for each 
group. In Study 1, efficacy calculations were based on 
total worm counts (number of animals with ≥ 1 worm 
and geometric mean worm counts per sex and per 
group). The data distribution was considered normal and 
a parametric analysis of variance was used to test for a 
treatment group effect. In Study 2, the primary efficacy 
parameter to evaluate the preventive efficacy of imida-
cloprid 10%/moxidectin 1% spot-on formulation against 
L3/L4 of A. abstrusus, as well as the treatment efficacy 
against adult worms, was the number of viable adult 
worms at necropsy. Because the data were not normally 
distributed, the Wilcoxon-Mann-Whitney test was used 
to test for a treatment group effect.
In Study 3, the viable A. abstrusus worm counts 
were also not normally distributed. For this reason, the 
non-parametric Wilcoxon rank-sum test (two-tailed; 
alpha = 0.05) was used to test for treatment group effects.
In Studies 1 and 3, another lungworm, Troglostrongylus 
brevior, was found during necropsy. Troglostrongylus bre-
vior L1 seems morphologically very similar to A. abstru-
sus L1. Therefore, the fecal larval results at necropsy were 
used for informational purposes only and no further sta-
tistical analysis was performed: the fecal larval counts 
had to be estimated as combined A. abstrusus and T. bre-
vior L1 counts and no valid data could be generated for 
the reduction of fecal A. abstrusus L1 excretion.
All analyses were performed using SAS version 9.2 
or 9.3 (SAS Institute, Cary, North Carolina, USA), 
respectively.
Results
Fecal examinations
Fecal examinations demonstrated L1 shedding in all cats 
in the untreated control groups and in the treatment 
group of Study 2 (before treatment) between SD 40 and 
SD 50, thus confirming patency and successful experi-
mental A. abstrusus infections. All treatment and preven-
tion groups had negative fecal larval counts at necropsy.
Efficacy evaluation
In all three studies, the requirements for adequate infec-
tion were met, as all control cats were infected and har-
bored the required minimum number of parasites. The 
results are summarized in Table 2.
Study 1
At necropsy, control cats (group 1.1) harbored 6–39 
viable worms and a total of 11–68 (viable + non-viable) 
adult A. abstrusus in their lungs (GM: 28.8). The total 
worm counts in the treated group 1.2 (single treatment 
imidacloprid 10%/moxidectin 1% spot-on formulation 
at 36 dpi) were reduced by 88.3% (t-test: t(21) = 4.70, 
P = 0.0001).
Study 2
In the control group (group 2.1), 4–42 viable worms (GM: 
14.3) and a total of 4–44 worms (viable and non-viable) 
(GM: 14.4) were discovered at necropsy. The preventive 
group 2.2 (treatment with imidacloprid 10%/moxidectin 
1% spot-on formulation 10 days before and 18 days after 
Table 2 Efficacy of imidacloprid 10%/moxidectin 1% spot‑on in prevention and treatment of Aelurostrongylus abstrusus infection as 
determined in three controlled studies
a Efficacy calculation based on total worm counts
b Efficacy calculation based on viable worm counts
c Geometric mean (range)
*Significantly different (P < 0.05) compared to control group
**Lower bound of 95% confidence interval greater than 10% of the geometric mean
Abbreviation: na, not applicable
Study Group Cats with ≥ 1 worm Totala/viableb worm 
 burdenc
Efficacy (%) Adequacy 
of 
infection
1 (1) Control 8 28.8 (11–68)a na Yes**
(2) Advocate® (SD 36) 7 3.4* (0–18)a 88.3 na
2 (1) Control 8 14.3 (4–42)b na Yes**
(2) Advocate® SD 10 + SD 18 0 0*b 100 na
(3) Advocate® SD 53, 81, 109 1 0.1* (0–1)b 99.4 na
3 (1) Control 8 32.6 (3–86)b na Yes**
(2) Advocate® SD 4 + SD 24 0 0*b 100 na
(3) Advocate® SD 10 + SD 18 0 0*b 100 na
(4) Advocate® SD 20 + SD 8 0 0*b 100 na
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infection) did not harbor any nematodes at necropsy, 
resulting in a preventive efficacy of 100%. In the treat-
ment group 2.3 (treatment after patency was reached 
with imidacloprid 10%/moxidectin 1% spot-on formula-
tion on days 53, 81 and 109 post-infection), one animal 
harbored one viable worm at necropsy (efficacy 99.4%). 
In both of these groups, reductions were significant com-
pared to the untreated control group (Wilcoxon rank 
sums test: Z = 3.5366 and 3.4562, respectively, P < 0.05).
Study 3
In Study 3, three different sets of pre- and post-infec-
tion preventative treatments, the latter then during pre-
patency, with imidacloprid 10%/moxidectin 1% spot-on 
formulation at monthly intervals starting at 4, 10 or 20 
days before infection were evaluated. The control group 
3.1 harbored 3–86 viable worms (GM: 32.6) and a total 
of 3–88 worms (GM: 34.2). No viable worms were found 
at necropsy in any of the three prevention groups. One 
dead worm was found in one cat in group 3.3 (treatment 
on SD 10 and SD 18). Live L1 were found in the lungs 
of 6 out of 8 control cats at necropsy, while no live lar-
vae were found in any of the treated cats. One cat in 
group 3.4 (treatment on SD 20 and SD 8) had one dead 
larva. All three imidacloprid 10%/moxidectin 1% treated 
groups showed a significant reduction in viable and total 
worm counts compared to the control group (Wilcoxon 
rank sums test: for viable counts, Z = − 3.5336 for all 3 
pair-wise comparisons, P < 0.05, for total worm counts, 
Z = − 3.5366, − 3.4562 and − 3.5366, respectively, 
P < 0.05). Efficacy based on geometric mean viable worm 
counts for Advocate® was 100% in all three study groups.
Troglostrongylus brevior infection
Unintended infections with T. brevior at necropsy (worm 
count range 2–23) were detected in six control cats in 
Study 1, as well as seven control cats (worm count range 
1–4) and two cats (worm count range 1–2) in treatment 
groups 3.2 and 3.4, respectively, in Study 3. The numbers 
of detected T. brevior were not used for efficacy calcu-
lations. In Study 2, no coinfections with T. brevior were 
observed at necropsy. As T. brevior shed L1, which are 
morphologically almost identical to those shed by A. 
abstrusus and no L1 differentiation was performed, larval 
numbers in feces potentially represent the larvae of both 
species.
Safety evaluation and general health
Treatment-related adverse events did not occur in any 
of the three studies. However, signs of lungworm infec-
tions such as tachypnea/dyspnea or sneezing, especially 
in the control groups, were frequently observed. This 
correlated with the severity of macroscopic findings at 
necropsy (Fig. 2). For example, in Study 2, all cats in the 
untreated control group showed macroscopic changes 
of the lung tissue: five out of eight lungs were described 
as “inhomogeneous” and four of these had a “meat-like” 
consistency. All of the eight lungs showed atelectasis 
to a varying extent. Three out of eight lungs showed 
nodules and the other five had vesicles on the surface. 
Even though the cats in the treatment group showed 
mostly normal lung tissue, all of them had white nod-
ules varying in number and size and, in the lungs of one 
cat, atelectatic areas were observed. These changes are 
indicative of tissue damage caused by verminous pneu-
monia occurring before patency is reached.
In contrast, cats in the prevention group showed no 
or only small macroscopic changes to the lungs, i.e. the 
lung tissue of one cat was dark red (otherwise normal) 
and another had a few white nodules.
Discussion
Reduction of the worm burden needs to be at least 90% 
in order to claim efficacy of an anthelmintic (VICH 
Guidelines 7 and 20 [36, 37]). A single treatment with 
the imidacloprid 10%/moxidectin 1% topical formula-
tion at the recommended minimum treatment dose of 
10 mg/kg bw imidacloprid and 1 mg/kg bw moxidectin 
resulted in 88.3% efficacy in Study 1. In contrast, a sin-
gle application of the same dose in naturally infected 
cats, compared with a control oral formulation contain-
ing 18.75% fenbendazole (Panacur®, MSD), resulted in 
100% reduction in fecal larval shedding [24]. However, 
as the duration of infection and the true parasite bur-
den is unknown in naturally infected cats, a direct com-
parison to experimental infections is not feasible.
Likewise, three treatments in monthly intervals using 
the same imidacloprid 10%/moxidectin 1% formulation 
and dosage resulted in an efficacy of 99.4% in Study 2. 
Fig. 2 Lungs of A. abstrusus‑infected cats at necropsy (Study 2). a 
Control group: verminous pneumonia, multifocal subpleural nodules, 
areas of consolidation, diffuse emphysema. b Prevention group: 
normal lung tissue, acute congestion. c Treatment group: multifocal 
subpleural nodules (orange circles), acute congestion
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This is concordant with other findings, i.e. that a com-
plete reduction of larval shedding following a single treat-
ment with a macrocyclic lactone is typically not achieved 
[23, 28], particularly when patent infections with high 
numbers of lungworms are present.
Efficacy in preventing such patent infections was 
assessed in Studies 2 and 3 and this is, to our knowledge, 
the first report of prevention of the establishment of a 
patent A. abstrusus infection with the use of a topical 
imidacloprid 10%/moxidectin 1% formulation at monthly 
intervals. This demonstrates its efficacy against larval and 
adult stages of A. abstrusus, as the treatment time points 
in Studies 2 and 3 were chosen based on the time points 
of the moults of A. abstrusus L3 (5–6 dpi) and L4 (8–9 
dpi) [14]. Thus, A. abstrusus were expected to be L3 up 
to 4 dpi, L4 up to 7 dpi, L5 (immature adults) at around 
14 dpi and mature adults from 25 dpi, the earliest time 
point at which worms have been reported to lay eggs in 
the lungs [39]. However, due to the known persistence 
of moxidectin in the treated animals, it cannot be clearly 
stated which of the larval stages were actually affected. 
The complete efficacy against larval and adult stages of A. 
abstrusus has previously only been described for a topi-
cal combination formulation containing the avermectin 
eprinomectin based on larval counts [28]. After a second 
treatment with this formulation at monthly intervals, effi-
cacy remained > 99% up to the end of follow-up, but at 
necropsy, lungworm burdens were only reduced by 75% 
compared to controls [29]. This illustrates the short-
comings of efficacy calculations based on larval counts, 
as larval shedding may have stopped while adult worms 
persisted in the lung tissue [15], as also confirmed by the 
presence of specific antibodies against A. abstrusus in 
cats without larval excretion [40]. Furthermore, larval 
counts are influenced by irregular shedding and the limi-
tations of the Baermann technique [15, 41, 42]. Because 
of these shortcomings, efficacy calculations in the studies 
presented here were to be based on adult worm counts in 
the lung tissue. Therefore, necropsies were performed to 
assess the worm burden in the lungs. Concerning the dif-
fering numbers of inoculated larvae in the three studies 
(800 L3 in Study 1, 300 L3 in Studies 2 and 3), it should 
be noted that the inoculation dosage of 800 larvae led 
to a variety of clinical and respiratory signs, as well as 
remarkably affected lung tissue. Due to animal welfare 
reasons, Studies 2 and 3 were conducted with a lower 
(300 L3) inoculation dose. However, despite the lower 
inoculation dose, the adequacy of infection was still met 
in both studies (see Table  2). In two of the studies pre-
sented here, it became evident at necropsy that some cats 
were infected with a second lungworm species, T. brev-
ior. Such a co-infection can easily be overlooked when 
only larval counts are assessed, as the L1 of A. abstrusus 
and T. brevior are morphologically almost identical [43]. 
As no other differentiation between larvae was per-
formed before the infection of snails (L1) and cats (L3), 
a partial infection with low numbers of T. brevior cannot 
be excluded. However, as numbers of identified T. brev-
ior were considerably low, results were excluded from 
efficacy calculations. In contrast, adult specimens of A. 
abstrusus and T. brevior can be readily distinguished [26].
Prevention of patent infections by the use of anthel-
mintic drugs requires efficacy against early larval stages 
(L3 and/or L4) of A. abstrusus. This is highly desirable as 
verminous pneumonia with tissue damage and its clinical 
consequences may occur before the onset of patency [15, 
17]; this is also evident from the macroscopic findings at 
necropsy (Fig. 2). Furthermore, preventive treatment can 
be a contribution to an effective epidemiological control 
of A. abstrusus infections in cats, since even after curative 
treatment, infected cats still shed L1 for up to 8.9 ± 2.0 
days [44]. Because of its pharmacokinetic properties, 
such as a longer half-life and its favorable safety pro-
file, moxidectin has been a promising candidate for the 
chemoprevention of an A. abstrusus infection [31, 45]. 
In other parasites, the chemopreventive properties of the 
moxidectin steady-state have already been shown, e.g. 
the formulation of imidacloprid 10%/moxidectin 1% pro-
tects cats against Dirofilaria immitis for 28 days after the 
last treatment when administered four times at monthly 
intervals [32]. Here, in two separate controlled laboratory 
studies, the chemoprevention of A. abstrusus infections 
with a topical imidacloprid 10%/moxidectin 1% formu-
lation with 100% efficacy when administered twice at a 
monthly interval is shown.
Conclusions
The monthly administration of Advocate® reliably elimi-
nated early larval stages and thereby prevented lung dam-
age from and a patent infection with A. abstrusus in cats. 
Regarding treatment, a single application of Advocate® 
reduced the worm burden, but it did not sufficiently clear 
the infection. In contrast, three monthly treatments were 
safe and highly efficacious against A. abstrusus.
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